Go William 4

4 · Janux Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 5, 2026

Janux (JANX) CMO William Go Receives RSU Award

What Happened

William Go, Chief Medical Officer of Janux Therapeutics (JANX), was granted a total of 198,000 equity awards on February 2, 2026: 44,000 shares and an additional 154,000 derivative awards. The reported acquisition price is $0 per share, so the filing shows $0 as the transaction value. These are awards (RSUs/derivative equity) rather than open-market purchases or sales.

Key Details

Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (within the 2-business-day reporting window).
Shares/awards: 44,000 RSUs (grant) and 154,000 derivative awards (total 198,000 units); price reported $0.00 per share.
Shares owned after transaction: Not specified in the information provided in this summary/filing excerpt.
Footnotes:
- F1: The granted RSUs represent contingent rights to receive common stock; they vest in four equal annual installments beginning February 1, 2027.
- F2: States a vesting schedule (25% on Feb 26, 2027, then monthly over three years) for option-type awards—included in the filing as provided.
Filing timeliness: Filed Feb 4, 2026 for a Feb 2, 2026 transaction (appears timely).

Context

These were equity awards (RSUs/derivative awards). RSUs are contingent rights to future shares and are not immediate cash purchases or sales; their value depends on future stock price and vesting. The filing records the grant at $0 per share, which is standard for many restricted awards; it does not mean the economic value is zero.

Form 4

Period: 2026-02-02

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-02-02+44,000→ 44,000 total
Award
Stock option (right to buy)
[F2]
2026-02-02+154,000→ 154,000 total
Exercise: $13.99Exp: 2036-02-01→ Common Stock (154,000 underlying)

Footnotes (2)

[F1]Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on February 1, 2027.
[F2]25% of the shares subject to the option vest on February 26, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.

Signature

/s/ James Pennington, Attorney-in-Fact|2026-02-04

1 file